Search Results - "Nussenzveig, Roberto H."

Clinical utility of next‐generation sequencing in the diagnosis of hereditary haemolytic anaemias by Agarwal, Archana M., Nussenzveig, Roberto H., Reading, Noel S., Patel, Jay L., Sangle, Nikhil, Salama, Mohamed E., Prchal, Josef T., Perkins, Sherrie L, Yaish, Hassan M., Christensen, Robert D.

“…Summary Hereditary haemolytic anaemias are genetically and phenotypically heterogeneous disorders characterized by increased red cell destruction, with…”
Get full text

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA by Swami, Umang, Zimmerman, Raquel Mae, Nussenzveig, Roberto H, Hernandez, Edgar Javier, Jo, Yeonjung, Sayegh, Nicolas, Wesolowski, Sergiusz, Kiedrowski, Lesli A, Barata, Pedro C, Lemmon, Gordon Howard, Bilen, Mehmet A, Heath, Elisabeth I, Nandagopal, Lakshminarayan, Babiker, Hani M, Pal, Sumanta K, Lilly, Michael, Maughan, Benjamin L, Haaland, Benjamin, Yandell, Mark, Sartor, Oliver, Agarwal, Neeraj

“…-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to -mutated prostate cancer. The…”
Get full text

Quest for Ideal Composite Biomarkers for Response to Immunotherapies by Swami, Umang, Nussenzveig, Roberto H, Agarwal, Neeraj

“…In the CheckMate 275 study, composite biomarkers appear to better predict response to immunotherapy over individual ones. Nevertheless, the path forward needs…”
Get full text

Novel exon 2 α spectrin mutation and intragenic crossover: three morphological phenotypes associated with four distinct α spectrin defects by Swierczek, Sabina, Agarwal, Archana M, Naidoo, Kubendran, Lorenzo, Felipe R, Whisenant, Jonathan, Nussenzveig, Roberto H, Agarwal, Neeraj, Coetzer, Theresa L, Prchal, Josef T

“…Hereditary pyropoikilocytosis is a severe hemolytic anemia caused by spectrin deficiency and defective spectrin dimer self-association, typically found in…”
Get full text

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer by Swami, Umang, Graf, Ryon P, Nussenzveig, Roberto H, Fisher, Virginia, Tukachinsky, Hanna, Schrock, Alexa B, Li, Gerald, Ross, Jeffrey S, Sayegh, Nicolas, Tripathi, Nishita, Mathew Thomas, Vinay, Oxnard, Geoffrey R, Antonarakis, Emmanuel S, Agarwal, Neeraj

“…Intensification of androgen deprivation therapy (ADT) with either docetaxel or androgen receptor axis-targeted therapies (ARAT) are the current standard of…”
Get full text

Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement by Swami, Umang, Nussenzveig, Roberto H, Haaland, Benjamin, Agarwal, Neeraj

Get full text

External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer by Swami, Umang, Sayegh, Nicolas, Jo, Yeonjung, Haaland, Benjamin, McFarland, Taylor Ryan, Nussenzveig, Roberto H, Goel, Divyam, Sirohi, Deepika, Hahn, Andrew W, Maughan, Benjamin L, Goldkorn, Amir, Agarwal, Neeraj

“…Approximately 20% of men with metastatic castration-sensitive prostate cancer (mCSPC) progress within 1 year of treatment, and biomarkers to identify them up…”
Get full text

JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome by Lin, Pei, MD, Luthra, Rajyalakshmi, PhD, Nussenzveig, Roberto H., PhD, Medeiros, L. Jeffrey, MD

“…Summary The 3q21q26 syndrome is recognized as a distinct clinicopathologic entity. Patients have a myeloid neoplasm associated with 3q21q26 cytogenetic…”
Get full text

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA by Agarwal, Neeraj, Pal, Sumanta K., Hahn, Andrew W., Nussenzveig, Roberto H., Pond, Gregory R., Gupta, Sumati V., Wang, Jue, Bilen, Mehmet A., Naik, Gurudatta, Ghatalia, Pooja, Hoimes, Christopher J., Gopalakrishnan, Dharmesh, Barata, Pedro C., Drakaki, Alexandra, Faltas, Bishoy M., Kiedrowski, Lesli A., Lanman, Richard B., Nagy, Rebecca J., Vogelzang, Nicholas J., Boucher, Kenneth M., Vaishampayan, Ulka N., Sonpavde, Guru, Grivas, Petros

“…BACKGROUND Biomarker‐guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue…”
Get full text

Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer by Ledet, Elisa M., Lilly, Michael B., Sonpavde, Guru, Lin, Edwin, Nussenzveig, Roberto H., Barata, Pedro C., Yandell, Mark, Nagy, Rebecca J., Kiedrowski, Lesli, Agarwal, Neeraj, Sartor, Oliver

“…Background Somatic alterations in circulating tumor DNA (ctDNA) may be associated with treatment response or prognosis in prostate cancer (PCa). The goal was…”
Get full text

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer by Sonpavde, Guru, Agarwal, Neeraj, Pond, Gregory Russell, Nagy, Rebecca J., Nussenzveig, Roberto H., Hahn, Andrew W., Sartor, Oliver, Gourdin, Theodore Stewart, Nandagopal, Lakshminarayanan, Ledet, Elisa M., Naik, Gurudatta, Armstrong, Andrew J., Wang, Jue, Bilen, Mehmet Asim, Gupta, Shilpa, Grivas, Petros, Pal, Sumanta K., Lanman, Richard B., Talasaz, AmirAli, Lilly, Michael B.

“…Background Because cell‐free DNA (cfDNA) analysis facilitates the noninvasive genomic profiling of metastatic castration‐resistant prostate cancer (mCRPC), the…”
Get full text

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001 by Nussenzveig, Roberto H., Cortes, Jorge, Sever, Matjaz, Quintás-Cardama, Alfonso, Ault, Pat, Manshouri, Taghi, Bueso-Ramos, Carlos, Prchal, Josef T., Kantarjian, Hagop, Verstovsek, Srdan

“…Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive production of red blood cells. Patients with PV are at a risk…”
Get full text

Identification of Somatic Gene Signatures in Circulating Cell‐Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform by Lin, Edwin, Hahn, Andrew W., Nussenzveig, Roberto H., Wesolowski, Sergiusz, Sayegh, Nicolas, Maughan, Benjamin L., McFarland, Taylor, Rathi, Nityam, Sirohi, Deepika, Sonpavde, Guru, Swami, Umang, Kohli, Manish, Rich, Thereasa, Sartor, Oliver, Yandell, Mark, Agarwal, Neeraj

“…Purpose Progression from metastatic castration‐sensitive prostate cancer (mCSPC) to a castration‐resistant (mCRPC) state heralds the lethal phenotype of…”
Get full text

Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer by Hahn, Andrew W., Gill, David M., Nussenzveig, Roberto H., Poole, Austin, Farnham, Jim, Cannon-Albright, Lisa, Agarwal, Neeraj

“…The HSD3B1 (1245C) variant is predictive of response to ADT in castration sensitive prostate cancer (CSPC) and to ketoconazole in castration resistant prostate…”
Get full text

Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC) by Hahn, Andrew W, Gill, David M, Poole, Austin, Nussenzveig, Roberto H, Wilson, Sara, Farnham, James M, Stephenson, Robert A, Cannon-Albright, Lisa A, Maughan, Benjamin L, Agarwal, Neeraj

“…There are many treatment options available for men with metastatic castration-resistant prostate cancer (mCRPC). Yet, biomarkers predictive of differential…”
Get full text

Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting by Sayegh, Nicolas, Tripathi, Nishita, Nussenzveig, Roberto H., Thomas, Vinay Mathew, Tandar, Clara, Goel, Divyam, Nordblad, Blake, Sahu, Kamal Kant, Li, Haoran, L. Maughan, Benjamin, Agarwal, Neeraj, Swami, Umang

“…In patients with metastatic prostate cancer, overall survival after progression on an androgen receptor axis–targeted therapy (ARAT) is <2 yr, independent of…”
Get full text

Reversible binding of nitric oxide by a salivary heme protein from a bloodsucking insect by Ribeiro, J.M.C. (University of Arizona, Tucson, AZ), Hazzard, J.M.H, Nussenzveig, R.H, Champagne, D.E, Walker, F.A

“…The bloodsucking bug Rhodnius prolixus has a salivary vasodilator, previously characterized as a nitrovasodilator, with salivary smooth muscle-relaxing and…”
Get full text

The JAK kinase inhibitor CP‐690,550 supresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation by Manshouri, Taghi, Quintás‐Cardama, Alfonso, Nussenzveig, Roberto H., Gaikwad, Amos, Estrov, Zeev, Prchal, Josef, Cortes, Jorge E., Kantarjian, Hagop M., Verstovsek, Srdan

“…The somatic activating janus kinase 2 mutation (JAK2)V617F is detectable in most patients with polycythemia vera (PV). Here we report that CP‐690,550 exerts…”
Get full text

Siblings with severe pyruvate kinase deficiency and a complex genotype by Christensen, Robert D., Yaish, Hassan M., Nussenzveig, Roberto H., Agarwal, Archana M.

“…Siblings presented as neonates with severe jaundice and transfusion‐dependent hemolytic anemia. Next‐generation sequencing revealed both to have three…”
Get full text

Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden by Nussenzveig, Roberto H, Pham, Ha T, Perkins, Sherrie L, Prchal, Josef T, Agarwal, Archana M, Salama, Mohamed E

“…The frequency of co-existing JAK2(V617F)/MPL and JAK2(V617F)/JAK2 exon-12 mutations has not been previously investigated in MPNs. Poor survival was reported in…”
Get full text